Suzetrigine: Navigating Acute Pain with Non-Opioid Relief – 0.5 CE

Course Introduction: A New Era in Pain Management

For decades, managing severe pain after surgery or trauma has felt like a dangerous balancing act: powerful relief has meant accepting powerful risks. Opioids have dominated that landscape — effective, but often at the cost of addiction, dependence, and lives. With over 108,000 opioid-related deaths in 2022 alone, the urgency for safer alternatives has never been greater.

Enter what may be a turning point: Sugnatrigone (Vixs) — the first FDA-approved non-opioid painkiller designed to rival opioids in strength without triggering the brain’s addictive pathways. Fast-tracked by the FDA and described as an “important public health milestone,” this drug introduces a completely new approach to pain relief by targeting NAV 1.8 sodium channels in the peripheral nervous system, blocking pain at the source before it reaches the brain. This course will unpack the science, clinical evidence, benefits, limitations, and real-world challenges — including access and cost — behind what could be a breakthrough in the fight against the opioid crisis.